PMV Pharmaceuticals Statistics
Share Statistics
PMV Pharmaceuticals has 51.75M shares outstanding. The number of shares has increased by 0.71% in one year.
| Shares Outstanding | 51.75M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.15% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 41.42M |
| Failed to Deliver (FTD) Shares | 33 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 847.18K, so 1.64% of the outstanding shares have been sold short.
| Short Interest | 847.18K |
| Short % of Shares Out | 1.64% |
| Short % of Float | 1.94% |
| Short Ratio (days to cover) | 4.16 |
Valuation Ratios
The PE ratio is -2.16 and the forward PE ratio is -1.06.
| PE Ratio | -2.16 |
| Forward PE | -1.06 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0.66 |
| P/FCF Ratio | -2.63 |
| PEG Ratio | n/a |
Enterprise Valuation
PMV Pharmaceuticals Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 14.78, with a Debt / Equity ratio of 0.
| Current Ratio | 14.78 |
| Quick Ratio | 14.78 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.38 |
| Cash Flow / Debt | -65.33 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.31% and return on capital (ROIC) is -33.53%.
| Return on Equity (ROE) | -0.31% |
| Return on Assets (ROA) | -0.27% |
| Return on Capital (ROIC) | -33.53% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.09M |
| Employee Count | 63 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 2.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -29.78% in the last 52 weeks. The beta is 1.48, so PMV Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 1.48 |
| 52-Week Price Change | -29.78% |
| 50-Day Moving Average | 1.6 |
| 200-Day Moving Average | 1.66 |
| Relative Strength Index (RSI) | 46.36 |
| Average Volume (20 Days) | 203.47K |
Income Statement
In the last 12 months, PMV Pharmaceuticals had revenue of $0 and earned -$68.96M in profits. Earnings per share was $-1.44.
| Revenue | 0 |
| Gross Profit | -1.26M |
| Operating Income | -80.13M |
| Net Income | -68.96M |
| EBITDA | -78.88M |
| EBIT | - |
| Earnings Per Share (EPS) | -1.44 |
Balance Sheet
The company has $37.71M in cash and $13.29M in debt, giving a net cash position of $24.42M.
| Cash & Cash Equivalents | 37.71M |
| Total Debt | 13.29M |
| Net Cash | 24.42M |
| Retained Earnings | -310.00M |
| Total Assets | 223.50M |
| Working Capital | 176.06M |
Cash Flow
In the last 12 months, operating cash flow was -$55.66M and capital expenditures -$962.00K, giving a free cash flow of -$56.62M.
| Operating Cash Flow | -55.66M |
| Capital Expenditures | -962.00K |
| Free Cash Flow | -56.62M |
| FCF Per Share | -1.18 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
PMVP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -91.14% |
| FCF Yield | -69.03% |
Analyst Forecast
The average price target for PMVP is $5.5, which is 248.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $5.5 |
| Price Target Difference | 248.1% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -0.45 |
| Piotroski F-Score | 2 |